Literature DB >> 2724488

Nonaggressive obstetric management. An option for some fetal anomalies during the third trimester.

F A Chervenak1, L B McCullough.   

Abstract

Nonaggressive obstetric management was used in 13 cases of anomalous fetuses during the third trimester. Criteria that define these anomalies are (1) a very high probability of a correct diagnosis and (2) either (a) a very high probability of death as an outcome of the anomaly diagnosed or (b) a very high probability of severe and irreversible deficit of cognitive developmental capacity as a result of the anomaly diagnosed. On the basis of two approaches to obstetric ethics, we defend the legitimacy of nonaggressive management of third-trimester pregnancies complicated by fetal anomalies that meet these criteria.

Entities:  

Keywords:  Analytical Approach; Genetics and Reproduction; Professional Patient Relationship

Mesh:

Year:  1989        PMID: 2724488     DOI: 10.1001/jama.261.23.3439

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  4 in total

1.  Perinatal management of trisomy 18: a survey of obstetricians in Australia, New Zealand and the UK.

Authors:  D J C Wilkinson; L de Crespigny; C Lees; J Savulescu; P Thiele; T Tran; A Watkins
Journal:  Prenat Diagn       Date:  2013-10-30       Impact factor: 3.050

2.  Ethical Dilemmas in Postnatal Treatment of Severe Congenital Hydrocephalus.

Authors:  Dominic Wilkinson
Journal:  Camb Q Healthc Ethics       Date:  2016-01       Impact factor: 1.284

Review 3.  Ethical language and decision-making for prenatally diagnosed lethal malformations.

Authors:  Dominic Wilkinson; Lachlan de Crespigny; Vicki Xafis
Journal:  Semin Fetal Neonatal Med       Date:  2014-09-05       Impact factor: 3.926

4.  A post-mortem population survey on foetal-infantile end-of-life decisions: a research protocol.

Authors:  Laure Dombrecht; Kim Beernaert; Ellen Roets; Kenneth Chambaere; Filip Cools; Linde Goossens; Gunnar Naulaers; Luc De Catte; Joachim Cohen; Luc Deliens
Journal:  BMC Pediatr       Date:  2018-08-03       Impact factor: 2.125

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.